Combining Metformin and Drug-Loaded Kidney-Targeting Micelles for Polycystic Kidney Disease.

ABSTRACT:

Introduction

Autosomal dominant polycystic kidney disease (ADPKD) is the most common inherited kidney disease that leads to eventual renal failure. Metformin (MET), an AMP-activated protein kinase (AMPK) activator already approved for type 2 diabetes, is currently investigated for ADPKD treatment. However, despite high tolerability, MET showed varying therapeutic efficacy in preclinical ADPKD studies. Thus, newer strategies have combined MET with other ADPKD small molecule drug candidates, thereby targeting multiple ADPKD-associated signaling pathways to enhance therapeutic outcomes through potential drug synergy. Unfortunately, the off-target side effects caused by these additional drug candidates pose a major hurdle. To address this, our group has previously developed kidney-targ

SUBMITTER: Jiang K 

PROVIDER: S-EPMC9842834 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature